Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
about
Altered Biomarkers in Trophoblast Cells Obtained Noninvasively Prior to Clinical Manifestation of Perinatal DiseasePre-eclampsia part 2: prediction, prevention and management.Maternal circulating levels of transforming growth factor-β superfamily and its soluble receptors in hypertensive disorders of pregnancy.Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy.Integrated Proteomic and Metabolomic prediction of Term Preeclampsia.Serum Follistatin-like-3 was elevated in second trimester of pregnant women who subsequently developed preeclampsia.
P2860
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
@en
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
@nl
type
label
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
@en
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
@nl
prefLabel
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
@en
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
@nl
P2093
P356
P1476
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia
@en
P2093
Jonathan Lai
Kypros H Nicolaides
Marta Nucci
P304
P356
10.1159/000343220
P577
2012-11-13T00:00:00Z